Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib resistance, including dose escalation of the drug, combination treatments or novel targeted agents. Nilotinib is a second-generation tyrosine kinase inhibitor 30-50 fold more potent than imatinib with high affinity and selectivity on BCR/ABL, active against a wide range of mutant clones, except T315I mutation. Phase II trials of nilotinib showed high activity in imatinib-resistant or intolerant CML patients; front-line treatment of chronic phase Ph+ CML demonstrated rapid and stable cytogenetic responses and increasing molecular responses. We here review the development of nilotinib and the efficacy data in phase II and front-line trials.
Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL / Massimo, Breccia; Alimena, Giuliana. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - STAMPA. - 10:6(2009), pp. 530-536. [10.2174/138945009788488468]
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Titolo: | Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL | |
Autori: | ||
Data di pubblicazione: | 2009 | |
Rivista: | ||
Citazione: | Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL / Massimo, Breccia; Alimena, Giuliana. - In: CURRENT DRUG TARGETS. - ISSN 1389-4501. - STAMPA. - 10:6(2009), pp. 530-536. [10.2174/138945009788488468] | |
Handle: | http://hdl.handle.net/11573/32514 | |
Appartiene alla tipologia: | 01a Articolo in rivista |